Dhingra Kapil 4

What Happened Kapil Dhingra, a director of Black Diamond Therapeutics (BDTX), received a grant/award of 40,000 derivative shares (an option) on June 26, 2026. The grant is reported at a $0.00 per-share price (total reported value $0) and was recorded as an acquisition (transaction code A) on the Form 4 filed June 29, 2026. This was an award grant rather than a sale.

Key Details

• Transaction date: 2026-06-26; Form 4 filed: 2026-06-29 (filed within required reporting window).
• Grant: 40,000 derivative shares/options at $0.00 per share (total reported value $0).
• Shares owned after transaction: Not specified in the information provided.
• Footnote: The option vests and becomes exercisable in full on the earlier of (i) June 26, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to the reporting person’s continued service.
• Transaction code: A (award/grant); derivative instrument (option).

Context This entry documents a director compensation award (an option grant) that will vest in the future if service continues; no shares were reported sold or exercised at grant. Such awards are common for board compensation and do not by themselves indicate immediate buying or selling in the market.